The Role of Adaptive Immunity in Idiopathic Pulmonary Fibrosis: Hiding in Plain Sight

Duncan, Steven R.

doi:10.1007/978-1-62703-682-5_7

Cited by 4 publications

(2 citation statements)

References 190 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, features of autoimmunity have been described for IPF and are thought to contribute to IPF exacerbation, since autoantibody-reductive therapies have been shown to improve the lung function of IPF patients during acute exacerbation (Donahoe et al, 2015). These and other studies have shown that there are indeed alterations in the adaptive immune system of pulmonary fibrosis patients compared to healthy individuals (Duncan, 2014). Nonetheless, the evidence included here also shows that innate immunity (i.e., myeloid cells) is key in the development of fibrosis.…”

Section: Discussionmentioning

confidence: 96%

The diversity of myeloid immune cells shaping wound repair and fibrosis in the lung

2018

View full text Add to dashboard Cite

In healthy circumstances the immune system coordinates tissue repair responses in a tight balance that entails efficient inflammation for removal of potential threats, proper wound closure, and regeneration to regain tissue function. Pathological conditions, continuous exposure to noxious agents, and even ageing can dysregulate immune responses after injury. This dysregulation can lead to a chronic repair mechanism known as fibrosis. Alterations in wound healing can occur in many organs, but our focus lies with the lung as it requires highly regulated immune and repair responses with its continuous exposure to airborne threats. Dysregulated repair responses can lead to pulmonary fibrosis but the exact reason for its development is often not known. Here, we review the diversity of innate immune cells of myeloid origin that are involved in tissue repair and we illustrate how these cell types can contribute to the development of pulmonary fibrosis. Moreover, we briefly discuss the effect of age on innate immune responses and therefore on wound healing and we conclude with the implications of current knowledge on the avenues for future research.

show abstract

Section: Discussionmentioning

confidence: 96%

The diversity of myeloid immune cells shaping wound repair and fibrosis in the lung

2018

View full text Add to dashboard Cite

show abstract

“…Biologic agents (antibodies, cell surface receptor inhibitors) are being increasingly used to treat a variety of immunologically mediated and autoimmune disorders, and various combination therapies may be more effective but could increase the risk of adverse drug reactions. Additionally, combinations of immunosuppressive agents with antifibrotic drugs may enhance efficacy and prevent progression of various forms of ILD, which are characterized by extensive and progressive fibrosis, and a substantial proportion of patients with a difficult-to-treat disorder such as IPF, which has features of autoimmunity [12,13] and progressive fibrosis [14] may well benefit from a combination of immunosuppressive/ immunomodulatory and antifibrotic pharmacologic agents.…”

Section: How Should Immunosuppressive Therapies Be Monitored?mentioning

confidence: 99%

Immunosuppressive agents and interstitial lung disease: what are the risks?

Meyer

2014

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis

Meyer

2017

Expert Review of Respiratory Medicine

142

122

View full text Add to dashboard Cite

Many forms of interstitial lung disease (ILD) can progress to extensive fibrosis and respiratory failure. Idiopathic pulmonary fibrosis (IPF), which generally has a poor prognosis, has been thoroughly studied over the past two decades, and many important discoveries have been made that pertain to genetic predisposition, epidemiology, disease pathogenesis, diagnosis, and management. Additionally, non-IPF forms of ILD can have radiologic and histopathologic manifestations that mimic IPF, and making an accurate diagnosis is key to providing personalized medicine to patients with pulmonary fibrosis. Areas covered: This manuscript discusses current knowledge pertaining to the genetics, epidemiology, pathogenesis, and diagnosis of pulmonary fibrosis with an emphasis on IPF. The material upon which this discussion is based was obtained from various published texts and manuscripts identified via literature searching (e.g. PubMed). Expert commentary: Many genetic variants have been identified that are associated with risk of developing pulmonary fibrosis, and an improved understanding of the influence of both genomic and epigenomic factors in the development of pulmonary fibrosis is rapidly evolving. Because many forms of fibrosing ILD can have similar radiologic and histopathologic patterns yet have different responses to therapeutic interventions, making an accurate diagnosis of specific forms of pulmonary fibrosis is increasingly important.

show abstract

The Role of Adaptive Immunity in Idiopathic Pulmonary Fibrosis: Hiding in Plain Sight

Cited by 4 publications

References 190 publications

The diversity of myeloid immune cells shaping wound repair and fibrosis in the lung

The diversity of myeloid immune cells shaping wound repair and fibrosis in the lung

Immunosuppressive agents and interstitial lung disease: what are the risks?

Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis

Contact Info

Product

Resources

About